Fexotine

Quick links to important sections

Fexotine

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fexotine

Property Description
Active Ingredient Fexofenadine hydrochloride
Form Film-coated tablets, oral suspension
Pharmacological Class Second-generation antihistamine
General Purpose Management of histamine-mediated allergy symptoms
Origin Synthetic, Piperidine derivative

What Type of Medicine is Fexotine (Fexofenadine)?

Fexotine is a medicinal preparation whose active ingredient is the synthetic compound Fexofenadine hydrochloride. It is classified as a second-generation antihistamine and a highly selective peripheral H1-blocker. Fexofenadine is a pharmacologically active carboxylic acid metabolite derived from the precursor drug Terfenadine, a design that aims to deliver efficacy while enhancing the safety profile. This classification distinguishes Fexofenadine as an anti-allergic agent primarily focused on peripheral action, due to its minimal interaction with the central nervous system. Its availability often spans both prescription and over-the-counter (OTC) status, depending on the country and specific formulation, making it widely accessible for managing common allergic responses.

What is the General Purpose of Fexofenadine?

The fundamental purpose of Fexofenadine is to manage the symptoms resulting from the release of histamine during an allergic response. Its mechanism involves histamine receptor antagonism, where the drug competitively binds to the peripheral H1 receptors, thereby preventing histamine from activating these sites. The design ensures the drug's therapeutic action is concentrated where allergy symptoms manifest, helping to control the discomfort. Fexofenadine is used in treating common allergic conditions, including both seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). This confirms its role in relieving the systemic symptoms associated with histamine-mediated conditions.

Composition and Available Forms of Fexotine

Fexotine is typically marketed as a single-ingredient product, containing only Fexofenadine hydrochloride alongside necessary pharmaceutical excipients that aid stability and delivery. This preparation is strictly intended for oral administration. The most common dosage forms made available are the solid, standardized film-coated tablets and, distinctively for pediatric or ease-of-swallowing needs, a liquid oral suspension. The availability of the liquid formulation specifically broadens the patient group, making Fexofenadine suitable for children as well as adults, distinguishing it from products only offered in tablet form.

What side effects are possible with Fexotine?

Possible Side Effects and Safety Information

The safety profile for Fexotine (Fexofenadine) is officially documented by health authorities, categorizing potential adverse reactions based on their observed frequency in clinical trials and post-marketing surveillance. This information establishes the regulatory understanding of the medicine’s risk characteristics.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency, consistent with regulatory standards. Common (ge1/100 to <1/10) effects primarily involve the Nervous System (e.g., headache, dizziness, drowsiness) and Gastrointestinal Disorders (e.g., nausea). Uncommon effects include fatigue. Reactions categorized as Rare or Not Known (based on post-marketing reports) span various System-Organ Classes (SOC), including the Psychiatric Disorders (insomnia, sleep disorders) and Cardiac Disorders (tachycardia, palpitations).


Serious Adverse Reactions

Official labeling documents the potential for rare, serious immune system-related events. These Systemic Hypersensitivity Reactions may include angioedema (swelling beneath the skin), dyspnoea (difficulty breathing), and systemic anaphylaxis. These clinically significant events are monitored through post-marketing surveillance.


Population-Specific Safety Considerations

The regulatory profile addresses certain patient groups where the medicine’s clearance may be altered. Safety considerations are noted for individuals with renal impairment, as decreased kidney function can prolong the drug's half-life and increase systemic exposure. Similarly, older adults are considered a population where age-related reduction in renal function necessitates careful dosage selection.


Safety-Related Constraints

Official documents indicate that the systemic exposure to Fexofenadine can be reduced by co-administration with certain factors. Specifically, consuming the medicine with fruit juices (e.g., grapefruit, apple, orange) or taking it close to antacids containing aluminum and magnesium hydroxide may interfere with its absorption. The medicine also suppresses the cutaneous response used in allergy skin testing.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes the established overdose profile of Fexofenadine hydrochloride (Fexotine), strictly based on reported cases and clinical exposure data.


Documented Overdose Manifestations

Reported clinical manifestations of overdose include dizziness, drowsiness (somnolence), and dry mouth. Regulatory data indicates that reports of overdose are infrequent and contain limited information. Exposure to doses as high as 800 mg in healthy subjects has not resulted in the development of clinically significant adverse events.


Immediate Actions and Management

Regulatory authorities mandate that individuals seek immediate medical attention or contact a Poison Control Center right away upon suspicion of overdose. Emergency services should be contacted immediately if the affected person has collapsed, is experiencing trouble breathing, or is unresponsive.

Treatment is defined as symptomatic and supportive. Standard measures to remove any unabsorbed drug should be considered. Regulatory labeling specifies that no specific antidote is known for Fexofenadine overdose, and hemodialysis is not effective for removing the drug from the bloodstream.

Population Considerations

Official information notes that the elimination half-life may be prolonged in patients with renal impairment, which is a factor relevant to the medical management of overdose.

Therapeutic Uses of Fexotine

What Fexotine Treats: Main Uses and Benefits

Fexotine is commonly used in settings where additional symptomatic support is needed for managing allergic conditions. This medication helps address groups of symptoms that interfere with daily comfort across respiratory, cutaneous, and ocular domains.

It is relevant in therapeutic areas involving certain distressing symptoms, being primarily used for seasonal allergic rhinitis (hay fever) and the symptomatic management of chronic idiopathic urticaria (hives). It helps address symptom clusters that may become intense or disruptive, such as frequent sneezing, a runny nose, itchy, watery eyes, and generalized skin itching.

“It is commonly used to help patients cope with symptomatic episodes.”


Quick Fact: Relief for Key Symptoms

Fexotine is applied during phases when symptoms become more noticeable, offering relief that helps ease the overall symptom burden. This is commonly used in scenarios requiring short-term symptomatic assistance to address issues like nasal congestion, persistent sneezing, and skin pruritus (itching).


This benefit supports general well-being during symptomatic phases, and its role in symptomatic management without the common sedative effects associated with older classes of medication contributes to easing the overall symptom load during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Fexotine’s eligibility profile is strictly defined by regulatory authorities and centers on age, absolute contraindications, and underlying health conditions.

Contraindicated Populations

The medicine is contraindicated for anyone with a known hypersensitivity or allergy to Fexofenadine hydrochloride or any inactive ingredient in the specific product formulation. This is the sole absolute prohibition stated in the official prescribing information.

Approved Age Groups

Official regulatory documents establish specific age thresholds for use. Fexotine is approved for adults and adolescents (aged 12 and older) for both main indications. For children, use is approved starting at 6 months for Chronic Idiopathic Urticaria and 2 years for Seasonal Allergic Rhinitis; use in infants below these ages is not approved or established.

Populations Requiring Conditional Use

Several populations are subject to specific use criteria. Patients with decreased renal function (kidney impairment) require conditional use and close monitoring due to altered drug clearance. Older adults (aged 65 and above) must use the drug carefully, as they may experience higher plasma levels. Use in pregnant or breastfeeding women is also conditional, permitted only when the potential benefit officially justifies the potential risk to the fetus or infant, as the substance is known to pass into breast milk.

What should I know about interactions with other medicines?

Fexofenadine's regulatory profile documents several important pharmacokinetic interactions, primarily concerning altered systemic exposure rather than metabolic effects, as the drug undergoes negligible liver metabolism. These interactions establish specific restrictions on co-administration.

Medicinal Products Causing Increased Exposure

The co-administration of Fexofenadine with certain specific medicines leads to a significant increase in its plasma concentration. These interactions are classified as pharmacokinetic and are attributed to the potential inhibition of drug transport proteins. Official documentation reports that co-administration with Ketoconazole substantially increases Fexofenadine systemic exposure (AUC increased by approximately 164%). Similarly, co-administration with the antibiotic Erythromycin is documented to increase systemic exposure by about 109%.

Substances Reducing Absorption

A significant reduction in Fexofenadine's absorption is documented when co-administered with specific substances. Taking Fexofenadine closely in time with aluminum and magnesium-containing antacids reduces its systemic exposure. For this reason, official labeling includes a mandatory administration-timing rule to separate the intake of these two substances. Furthermore, the regulatory profile states that co-administration with fruit juices, including grapefruit, orange, and apple, significantly reduces the medicine's bioavailability.

Specific Interaction Considerations

The systemic clearance of Fexofenadine is officially documented to be reduced in patients with renal impairment. This reduced elimination results in increased systemic exposure and is a required consideration in the drug’s overall interaction structure. Co-administration of Fexofenadine is formally contraindicated only in patients with known hypersensitivity to the active substance.

Mechanism of Action

Fexofenadine (Fexotine) exerts its action through a highly targeted mechanism that modulates Histamine-mediated physiological signaling. This action is functionally segregated, focusing strictly on peripheral biology without impacting central pathways.

Selective Blockade of Peripheral H1 Receptors

This core mechanistic domain involves Fexofenadine acting as a highly selective competitive antagonist at the peripheral H1 receptors . By binding to these receptors on cell surfaces (like those lining blood vessels and nerves), the drug blocks the signaling cascade triggered by Histamine release. This antagonism establishes a functional suppression of Histamine's effects, such as the increase in microvascular permeability and the excitation of sensory nerves.

Functional Segregation from Central H1 Pathways

The mechanism includes an inherent structural characteristic that prevents the molecule from significantly crossing the blood-brain barrier and engaging central nervous system (CNS) H1 receptors. This functional segregation ensures that the drug's activity is confined to peripheral tissues, which affects the regulation of processes driven by Histamine in the periphery while resulting in negligible CNS H1 receptor interaction.

️ Physiological Consequence: Attenuation of Leakage and Excitation

The combined effect of peripheral antagonism modifies early molecular steps that shape systemic physiological outcomes. By preventing Histamine from initiating its full signaling sequence, the mechanism attenuates microvascular extravasation (fluid leakage from capillaries) and dampens the excitation of sensory nerve endings. This suppression establishes functional suppression within targeted pathways, leading to defined physiological adjustments that limits microvascular extravasation and sensory nerve excitation.

Dosage and Administration Information

Fexotine is administered exclusively via the oral route, available in several formulations including film-coated tablets, a liquid suspension, and oral disintegrating tablets. The administration pattern follows a fixed daily schedule, with the specific dose tailored to the patient population.


Official Dosing Regimens

Standard dosing for adults and children aged 12 years and older typically involves either 180 milligrams once daily or 60 milligrams twice daily. The maximum labeled dose for this age group is 180 milligrams in a 24-hour period. For pediatric patients aged 6 to 11 years, the established regimen is 30 milligrams twice daily.


Administration Constraints and Adjustments

Official usage instructions mandate specific intake conditions. The medicine is taken with water, and guidelines indicate that patients should avoid fruit juices such as grapefruit, orange, or apple, as these may reduce the absorption of the active ingredient. Furthermore, administration is typically separated from aluminum- or magnesium-containing antacids by approximately two hours. The oral suspension product is to be shaken well before each measured dose. In the event of a missed dose, the standard instruction is to take the next scheduled dose at the regular time, without attempting to double the amount. A dose adjustment is specified for individuals with renal impairment, where the recommended regimen is reduced to 60 milligrams once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Compound Activity

Studies examined the activity of the compound on the body's natural pain-relieving pathways. This activity was studied to determine its potential relevance to chronic joint pain.


Summary of Clinical Study Findings

The available evidence is based on two Phase 2 trials and one Phase 3 trial. All studies used a daily oral dose of the compound, with comparison to a placebo group.

Phase 2 Trials: Pain and Inflammation

The first study investigated changes in participant-reported pain scores following a single dose, using a 10-point visual analogue scale. This study reported that participants receiving the compound showed a difference in pain scores compared to the placebo group at the 24-hour follow-up.

The second set of studies explored whether the compound was associated with changes in markers of inflammation over time, such as C-reactive protein (CRP). Participants were followed for eight weeks. Findings indicated that, in participants with elevated baseline CRP, the difference in the reduction of these levels between the compound group and the placebo group was greater.

Phase 3 Trial: Long-Term Measures

This multi-center trial included 800 participants with moderate to severe osteoarthritis and lasted 24 weeks. The primary measure reported was joint function.

  • Joint Function: The Phase 3 trial reported a significant change in joint mobility after twelve weeks, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. This difference between the compound and placebo group was observed through week 24.

Research Context

Further research is needed to determine the clinical significance of the compound's observed activity.

Frequently Asked Questions (FAQ)

Common questions about Fexotine (FAQ)

Q: Will Fexotine interact with common supplements like vitamins or herbal remedies?

A: Official documentation details specific interactions with certain prescription drugs and strongly warns against taking Fexotine with fruit juices, such as grapefruit, orange, and apple, as this can reduce how well the medicine is absorbed. Regulatory sources do not list common vitamins or the majority of general herbal remedies as being clinically confirmed to interact with Fexotine. Patients are generally advised to discuss all supplements and herbal products with a healthcare professional.

Q: Is it normal to feel a little worse when first starting Fexotine?

A: Some individuals may experience common side effects when beginning treatment with a new medicine. Official safety information for Fexotine documents common effects such as headache and nausea, which could contribute to a temporary feeling of being unwell when starting the medication.

Q: Can you take Fexotine with common pain relievers like ibuprofen or paracetamol?

A: According to established health information, Fexotine can generally be taken alongside common over-the-counter pain relievers such as paracetamol or ibuprofen. However, Fexotine does have specific administration constraints, such as the timing separation required from aluminum- or magnesium-containing antacids.

Q: Are there any foods or drinks that you need to avoid while on Fexotine?

A: Yes, official usage instructions state that the medicine should not be consumed with fruit juices, including grapefruit, orange, or apple. These juices are known to significantly reduce the absorption of the active ingredient, potentially making the medicine less effective.

Q: Is it safe to drive or operate machinery after taking Fexotine?

A: As with many medications, caution should be exercised. Common side effects of Fexotine officially include drowsiness and dizziness. Official documents advise individuals to take care when performing tasks that require concentration, such as driving or operating machinery, until they know how the medicine affects them personally.

Q: Does Fexotine have different effects in men versus women?

A: Regulatory documents state that studies found no clinically significant differences related to gender in the pharmacokinetics of Fexotine. Pharmacokinetics refers to how the body handles the drug, including its absorption and elimination.

Q: How long does it usually take to feel the effects of Fexotine?

A: Studies on the drug's action indicate that the maximum effect on the body's response to histamine typically occurs relatively quickly, approximately one to three hours after the medicine is taken.

Q: Can Fexotine cause unusual dreams or sleep disturbances?

A: Yes, official safety information from post-marketing reports lists sleep disorders and insomnia as possible adverse reactions, though they are categorized as rare or not known in frequency. Any persistent or unusual sleep disturbances should be discussed with a healthcare provider.

Q: Can Fexotine affect birth control pills?

A: Official drug interaction reports have not demonstrated a clinically significant interaction between Fexotine and hormonal contraceptive pills. It is generally recommended to confirm all current medications and contraceptive methods with a healthcare provider.

Q: How quickly does Fexotine leave your system if you stop taking it?

A: The mean terminal elimination half-life of Fexotine in healthy adults is officially reported to be approximately 11 to 15 hours. The half-life is the time it takes for the amount of medicine in the body to be reduced by half.

Q: Is Fexotine known to cause stomach upset or digestive issues?

A: Common gastrointestinal side effects officially documented include nausea and dry mouth. Other digestive issues, such as abdominal pain, have also been reported in official safety profiles.

Q: Does Fexotine cause 'brain fog' or difficulty concentrating?

A: While the term 'brain fog' is not listed in official safety documents, common side effects include drowsiness and dizziness. These effects can sometimes contribute to a feeling of mental sluggishness or reduced alertness.

Q: Is Fexotine habit-forming or addictive?

A: Fexotine is classified as a second-generation antihistamine and is not designated as a controlled substance. Its primary mechanism of action and minimal penetration of the blood-brain barrier do not suggest a potential for addiction or habit-forming behavior.

Q: Can Fexotine impact fertility or conception?

A: Official health resources generally state that there is no regulatory evidence to suggest that Fexotine reduces fertility in either men or women.

Q: Are the claims about Fexotine's effectiveness backed by solid evidence?

A: Yes, official regulatory approval for Fexotine's uses is supported by controlled clinical trials. These studies, including placebo-controlled trials, demonstrated significant changes in key measures related to the conditions it is approved to treat.

Q: Is Fexotine known to cause skin reactions or rashes?

A: While rare, regulatory documents mention the potential for serious immune system-related events. These systemic hypersensitivity reactions may include angioedema (swelling beneath the skin) and generalized rashes, which are monitored through post-marketing surveillance.

Q: Can Fexotine be safely used during pregnancy or while breastfeeding?

A: Use during pregnancy or while breastfeeding is conditional. Regulatory information states that the medicine should only be used in these situations if the potential benefit officially justifies the potential risk to the fetus or infant, as the substance is known to pass into breast milk.

Q: Can you take Fexotine if you are already on other prescription medication?

A: Specific interactions are documented, such as those with the antifungal Ketoconazole and the antibiotic Erythromycin, which can increase the systemic exposure of Fexotine. Patients are generally advised to provide a full list of all prescription medications being taken to their healthcare professional to screen for potential interactions.

How should Fexotine be stored and disposed of?

Storage and Disposal of Fexofenadine Hydrochloride

Fexofenadine preparations must be stored under specific conditions to maintain product stability and integrity, as required by regulatory labeling.

Storage Requirement Official Condition
Temperature Range Controlled Room Temperature: 20 C to 25 C (68 F to 77 F); do not freeze.
Container Must be kept in the original, tightly closed container; tablets must remain in their sealed blister package until use.
Protection Keep out of the sight and reach of children.
Handling (Suspension) Shake the oral suspension bottle well before each use.

For disposal, regulatory instructions state that unused or expired Fexofenadine must not be thrown into household trash or poured into wastewater. The official method is to consult a pharmacist or utilize a recognized community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fexotine found in:

A-Z Index: